Comparison of the therapeutic Effect of Radiofrequency and Intranasal Corticosteroid in Patients with Inferior Turbinate Hypertrophy due to Allergic Rhinitis

Clinical Trial of Comparison of Radiofrequency and Intranasal Corticosteroid Efficacies on Rhinomanometry, Symptom Severity, and Quality of Life in Patients With Inferior Turbinate Hypertrophy Due to Allergic Rhinitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014042417413N1

Enrollment

Registered

2014-05-08

Start date

2013-06-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic rhinitis. Vasomotor and allergic rhinitis

Interventions

Intervention 1: Radiofrequency of inferior turbinate under local anesthesia with lidocaine 10% in three point of inferior turbinate (first point in front of inferior turbinate and parallel to septum,

Treatment - Surgery

Treatment - Drugs

Radiofrequency of inferior turbinate under local anesthesia with lidocaine 10% in three point of inferior turbinate (first point in front of inferior turbinate and parallel to septum, second point par

Fluticasone 125 mcg intranasal spray, twice a day and every time one puff in each side of the nose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Allergic rhinitis patients with inferior turbinate hypertrophy referred to Baqiyatallah University of Medical Sciences Allergy Clinic without any age and gender limitations. Exclusion criteria: Patients with other obstruction lesions (e.g. polyp and tumor); severe septal deviation; asthma; cigarette smoking; chronic rhino-sinusitis; history of other medical therapies; history of sinus and nasal surgeries

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Rhinorrhea severity. Timepoint: Before treatment and one, three, and six months after intervention. Method of measurement: visual analogue score (0-10).;Itchy nose severity. Timepoint: Before treatment and one, three, and six months after intervention. Method of measurement: visual analogue score (0-10).;Nasal obstruction severity. Timepoint: Before treatment and one, three, and six months after intervention. Method of measurement: visual analogue score (0-10).;Facial pain severity. Timepoint: Before treatment and one, three, and six months after intervention. Method of measurement: visual analogue score (0-10).;Nasal airflow. Timepoint: Before treatment and one, three, and six months after intervention. Method of measurement: Rhinomanometry.;Quality of life. Timepoint: Before treatment and one, three, and six months after intervention. Method of measurement: Rhino-conjunctivitis quality of life questionnaire (RQLQ).	—

Measure

Time frame

Rhinorrhea severity. Timepoint: Before treatment and one, three, and six months after intervention. Method of measurement: visual analogue score (0-10).;Itchy nose severity. Timepoint: Before treatment and one, three, and six months after intervention. Method of measurement: visual analogue score (0-10).;Nasal obstruction severity. Timepoint: Before treatment and one, three, and six months after intervention. Method of measurement: visual analogue score (0-10).;Facial pain severity. Timepoint: Before treatment and one, three, and six months after intervention. Method of measurement: visual analogue score (0-10).;Nasal airflow. Timepoint: Before treatment and one, three, and six months after intervention. Method of measurement: Rhinomanometry.;Quality of life. Timepoint: Before treatment and one, three, and six months after intervention. Method of measurement: Rhino-conjunctivitis quality of life questionnaire (RQLQ).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamidreza Karimi Sari

Students’ Research Committee (SRC), Baqiyatallah University of Medical Sciences, Tehran, IR Iran

dr.karimih@yahoo.com+98 21 8126 4354

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026